{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:03:07Z","timestamp":1776196987524,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.radonc.2017.06.022","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T18:18:35Z","timestamp":1499278715000},"page":"311-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study"],"prefix":"10.1016","volume":"124","author":[{"given":"Ditte Sloth","family":"M\u00f8ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine Bj\u00f8rn","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina Maria","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel","family":"Dr\u00f8gem\u00fcller Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olfred","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine","family":"Schytte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azza Ahmed","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne Marquard","family":"Knap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa Haugaard","family":"Nyhus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiviann","family":"Ottosson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrik","family":"Sibolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Borissova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana","family":"Josipovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte","family":"Persson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ane Lindegaard","family":"Appelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2017.06.022_b0005","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Auperin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group","volume":"82","author":"Machtay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2005.02.010","article-title":"High-dose radiation improved local tumor control and overall survival in patients with inoperable\/unresectable non-small-cell lung cancer: long-term results of a radiation dose-escalation study","volume":"63","author":"Kong","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijrobp.2005.02.011","article-title":"Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer","volume":"62","author":"Schwarz","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/0284186X.2013.790560","article-title":"Inhomogeneous dose-escalation increases expected local control for NSCLC patients with lymph node involvement without increased mean lung dose","volume":"53","author":"Nielsen","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.radonc.2009.01.003","article-title":"Is pre-therapeutical FDG-PET\/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?","volume":"91","author":"Abramyuk","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0040","doi-asserted-by":"crossref","unstructured":"Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT skan. Radiother Oncol;91:386-92.","DOI":"10.1016\/j.radonc.2009.03.006"},{"key":"10.1016\/j.radonc.2017.06.022_b0045","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/0284186X.2013.868035","article-title":"Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer","volume":"53","author":"Schytte","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.radonc.2016.02.008","article-title":"Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy","volume":"118","author":"van Diessen","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0060","unstructured":"Hansen O, Knap MM, Khalil A, et al. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60Gy and 66Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC (Submitted to Radiother Oncol)."},{"key":"10.1016\/j.radonc.2017.06.022_b0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.semradonc.2003.10.003","article-title":"Errors and margins in radiotherapy","volume":"14","author":"van Herk","year":"2004","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijrobp.2005.05.045","article-title":"Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer","volume":"63","author":"Underberg","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0075","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ijrobp.2006.04.031","article-title":"Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients","volume":"65","author":"Wolthaus","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0080","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2967\/jnumed.111.101733","article-title":"Noise considerations for PET quantification using maximum and peak standardized uptake value","volume":"53","author":"Lodge","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2017.06.022_b0085","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ijrobp.2010.07.1977","article-title":"Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus","volume":"81","author":"Kong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0169-5002(99)00019-7","article-title":"Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients","volume":"24","author":"Martel","year":"1999","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2017.06.022_b0100","article-title":"A DICOM based radiotherapy plan database for research collaboration and reporting","volume":"489","author":"Westberg","year":"2014","journal-title":"J Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0105","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.06.022_b0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2012.03.005","article-title":"The PET-boost randomised phase IIdose-escalation trial in non-small cell lung cancer","volume":"104","author":"van Elmpt","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.radonc.2013.02.002","article-title":"Aortic dose constraints when reirradiating thoracic tumors","volume":"106","author":"Evans","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0125","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2007.14.7371","article-title":"Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74Gy) in stage III non-small-cell lung cancer: CALGB 30105","volume":"26","author":"Socinski","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0130","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0135","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.radonc.2013.08.017","article-title":"Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy","volume":"108","author":"Chen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0140","doi-asserted-by":"crossref","unstructured":"Wang K, Eblan MJ, Deal AM et al. Cardiac Toxicity After Radiotherapy for Stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90Gy. J Clin Oncol; 2017 [Epub ahead of print].","DOI":"10.1200\/JCO.2016.70.0229"},{"key":"10.1016\/j.radonc.2017.06.022_b0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2016.08.019","article-title":"Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose","volume":"121","author":"M\u00f8ller","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.06.022_b0150","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3109\/0284186X.2015.1062543","article-title":"Adaptation requirements due to anatomical changes in free-breathing and deep-inspiration breath-hold for standard and dose-escalated radiotherapy of lung cancer patients","volume":"54","author":"Sibolt","year":"2015","journal-title":"Acta Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814017304334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814017304334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T10:56:35Z","timestamp":1535626595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814017304334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0167814017304334"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2017.06.022","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2017.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}